NASDAQ:URGN

Urogen Pharma Stock News

Healthcare > Biotechnology

Buy URGN

*Your capital is at risk

$26.60

+0.0600 (+0.226%)

At Close: Jun 03, 2026

UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102

02:30pm, Friday, 14'th Feb 2025

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod

UroGen: Upcoming PDUFA, Some Concerns Remain

10:42am, Friday, 31'st Jan 2025

UroGen's Jelmyto, a gel-based mitomycin product for LG-UTUC, achieved $25.2mn in Q3 2024, marking a 20% YoY increase. Lead candidate UGN-102 shows promise in treating low-grade intermediate risk NMIBC

UroGen Pharma to Present at Upcoming Investor Conferences

08:00am, Thursday, 30'th Jan 2025

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

08:00am, Friday, 06'th Dec 2024

Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®

03:30pm, Thursday, 05'th Dec 2024

UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC

03:15pm, Thursday, 05'th Dec 2024

Wall Street Analysts Believe Urogen Pharma (URGN) Could Rally 209.92%: Here's is How to Trade

06:45pm, Monday, 02'nd Dec 2024

The mean of analysts' price targets for Urogen Pharma (URGN) points to a 209.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among a

UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs

08:00am, Monday, 02'nd Dec 2024

New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®

08:00am, Tuesday, 26'th Nov 2024

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today hi

UroGen Pharma: Choice Based On Near Term High Value PDUFA

08:02am, Wednesday, 13'th Nov 2024

Urogen's UGN-102 for bladder cancer presents a $5 billion market opportunity, prompting a continued "Strong Buy" rating despite past misjudgments. FDA approval by 06/2025 is crucial, with UGN-102 pote

UroGen Pharma Ltd. (URGN) Q3 2024 Earnings Call Transcript

05:12pm, Wednesday, 06'th Nov 2024

UroGen Pharma Ltd. (NASDAQ:URGN ) Q3 2024 Earnings Call Transcript November 6, 2024 10:00 AM ET Company Participants Vincent Perrone - Head of IR Liz Barrett - President and CEO Mark Schoenberg - CMO

Urogen Pharma (URGN) Reports Q3 Loss, Tops Revenue Estimates

10:15am, Wednesday, 06'th Nov 2024

Urogen Pharma (URGN) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.68 per share a year ago.

UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025

08:00am, Wednesday, 06'th Nov 2024

UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference

08:00am, Tuesday, 05'th Nov 2024

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, toda

UroGen Announces FDA Acceptance of its New Drug Application for UGN-102

04:30pm, Tuesday, 15'th Oct 2024

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by